Clinical Trial Update: Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating neoadjuvant nab-paclitaxel in HER2-negative high-risk breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Fondazione Michelangelo | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED